VISIT NUTRACEUTICALS WORLD at Booth 4872 TEST

Syngene Adds Senior Leadership in the U.S.

08.06.21

Alex Del Priore appointed Senior Vice President, Manufacturing Services, and Alan Collis appointed Vice President, Integrated Drug Discovery Services.

Syngene International, an integrated research, development, and manufacturing services company, has appointed Alex Del Priore as Senior Vice President, Manufacturing Services and Alan Collis as Vice President, Integrated Drug Discovery services. Both will be based in the U.S., one of the key markets for the company.

Alex Del Priore is a member of the Executive Committee and will provide strategic direction for growth of the manufacturing services business leveraging the company’s discovery and development strengths for an effective end-to-end offering. He is responsible for the growth of API outcomes from Syngene’s new facility in Mangalore and will develop a client base for the business in collaboration with the commercial and business development teams.

Alex will also be responsible for the growth of the large molecule operations and will oversee Syngene’s Biologics operations unit to continue building it as a diversified manufacturing business. He reports to Dr. Mahesh Bhalgat, Chief Operating Officer.

Alan Collis will be joining as the leader of the SynVent team. SynVent is Syngene's platform for integrated discovery and early development, delivering upon strategies built in collaboration with and on behalf of clients to advance novel molecules into clinical trials. He will be responsible for the formulation and implementation of Syngene's overall Integrated Drug Discovery (IDD) scientific strategy and will oversee the end-to-end execution of client programs. He reports to Kenneth Barr, Sr. Vice President, Discovery Services.

Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Ltd., said, "As we continue our rapid growth in the global CRO/CDMO marketplace, these hires align with Syngene's focus on providing end-to-end solutions for discovery, development, and manufacturing across a range of therapeutic areas and modalities. We look forward to having Alex and Alan on board, which will help strengthen our position as a partner in innovation for our clients and to steer Syngene towards new growth milestones."

Visit Syngene at CPhI North America Booth #1131